Clinical trials: Oral Anticoagulant Therapy
Covid19
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents…
- Trial name
- CORONA (NCT04518735)
- Testing
- Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
- Where
- Spain
- Volunteers
- 1,707 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Surgery, Oral, Hemorrhage
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
Aims: To investigate the incidence of bleeding complications during oral surgical procedures in patients medicated with DOACs. To investigate the perioperative and postoperative bleeding volume during oral surgical procedures in…
- Conditions
- Surgery, Oral, Hemorrhage, Postoperative Complications, Oral Surgical Procedures
- Trial name
- NCT04662515
- Testing
- Type of surgery, Dabigatran, Rivaroxaban
- Where
- 2 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Malmö University
Venous Thromboembolism
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
The aim of the study is to investigate the safety and tolerability of dabigatran etexilate solution in children aged less than 1 year, to demonstrate comparable PK/PD relationship to older children and adults and to confirm…
- Trial name
- NCT02223260
- Testing
- dabigatran
- Where
- 4 sites in Canada, France and 1 more
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
AIHEMAF - P "An Innovative Healthcare Model for AF Patients"
Non-profit observational study on the role of the community pharmacist and "the pharmacy of services" in the case management of patients suffering from atrial fibrillation and being treated with new generation oral anticoagulants
- Trial name
- AIHEMAF - P (NCT05086991)
- Testing
- Follow up
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Farmacia La Regina s.r.l.
Antiphospholipid Syndrome, Thrombosis
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
- Conditions
- Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- OBSTINATE (NCT04262492)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Stéphane Zuily
Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
Precision Antithrombotic Therapy
The goal of this observational study is to systematically analyze the relationship between trough/peak concentrations of novel oral anticoagulants (NOACs) and antiplatelet drugs with clinical events, aiming to provide high-level…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke
- Trial name
- NCT07654634
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Atrial Fibrillation (AF), Ischemic Stroke
Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy
Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.
- Trial name
- SAFER-DOAC (NCT07713537)
- Testing
- DOAC Level
- Where
- 2 sites in Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Blood Transfusion, Hip Fracture Surgeries
Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs
This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting…
- Conditions
- Blood Transfusion, Hip Fracture Surgeries, Geriatric, Bleeding Complications
- Trial name
- OPTIMIZEDOAC (NCT07309848)
- Where
- 7 sites in Netherlands
- Volunteers
- 374 people
- Sponsor
- St. Antonius Hospital
Cerebrosinovenous Thrombosis
Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis
The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard…
- Trial name
- NCT07523347
- Testing
- Rivaroxaban, Warfarin
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- Muhammad Aamir Latif
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅰ (NCT06901466)
- Testing
- Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Venous Thromboembolism
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
- Trial name
- VTE (NCT04041843)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅱ (NCT07007143)
- Testing
- Experimental: Aspirin monotherapy, Active Comparator: Aspirin+Clopidogrel
- Where
- China
- Volunteers
- 1,032 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Atrial Fibrillation
Impact of the Information Follow-up Given to Patients on Their Disease Understanding and Therapeutic Adherence in Patients Under Direct Oral Anticoagulants and With Atrial Fibrillation in a Cardiology Department
The primary objective of this study is to measure in patients addressed for Atrial Fibrillation (AF) in the Cardiology-Electrophysiology and Cardiac Stimulation Department of Bordeaux hospital, the impact of a specialized nurse…
- Trial name
- RYTHM-UP AOD (NCT03645564)
- Testing
- Specialized nurse consultation
- Where
- France
- Volunteers
- 221 people
- Sponsor
- University Hospital, Bordeaux
Atrial Fibrillation, Venous Thromboembolism
NOACs Use in AF or VTE (SUNSHINE Registry)
The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional…
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Oral Anticoagulant
- Trial name
- NCT05378308
- Testing
- Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Henan Provincial People's Hospital
Effect of Different Reagents., Oral Anticoagulant Therapy
Differences in Coagulation Test Kits
The aim of this study is to assess the effect of Innovin® reagent on laboratory results when compared with the Thromborel® S.
- Trial name
- NCT01109667
- Where
- Turkey (Türkiye)
- Volunteers
- 350 people
- Sponsor
- Yuksek Ihtisas Hospital
Atrial Fibrillation
Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)
The aim of FINACAF study is to evaluate the incidence and risk of stroke, systemic thromboembolic events, myocardial infarction, major bleeding events, and mortality in relation to different attitudes regarding stroke prevention…
- Trial name
- FinACAF (NCT04645537)
- Volunteers
- 400,000 people
- Sponsor
- Helsinki University Central Hospital
Ischemic Stroke, Patent Foramen Ovale
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects. Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and…
- Conditions
- Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm, Migraine
- Trial name
- CLOSE (NCT00562289)
- Testing
- aspirin, Antivitamins K or rivaroxaban or dabigatran or apixaban, Devices for PFO closure
- Where
- France
- Volunteers
- 664 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thrombosis, Cardiovascular Diseases
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
To perform a randomized clinical trial comparing continuing one month of treatment with heparin in patients with deep venous thrombosis to standard care using heparin for five days and oral warfarin for three months.
- Conditions
- Venous Thrombosis, Cardiovascular Diseases, Venous Thromboembolism
- Trial name
- NCT00005684
- Testing
- warfarin, heparin
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Anticoagulants, Compliance, Medication
Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation
The novel oral anticoagulants such as rivaroxaban, apixaban and dabigatran, specifically target either thrombin or factor Xa/IIa.
- Trial name
- NCT03666962
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Cui Yimin
Bleeding as Complication to Anticoagulation Therapy
Reporting of Adverse Events in Patients Treated With New Oral Anticoagulants
Serious adverse events in patients treated with new oral anticoagulants are underreported.
- Trial name
- NCT02107651
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Hvidovre University Hospital